Last reviewed · How we verify
Ricrolin+
Ricrolin+ is a therapeutic candidate developed at Mount Sinai that targets specific molecular pathways relevant to its indication, though the exact mechanism requires further clarification from clinical trial data.
At a glance
| Generic name | Ricrolin+ |
|---|---|
| Also known as | Epi-on (iontophoresis) |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a Phase 3 investigational drug from the Icahn School of Medicine at Mount Sinai, Ricrolin+ is being evaluated for efficacy and safety in its target indication. The specific molecular mechanism and target have not been widely disclosed in public literature, limiting detailed mechanistic characterization at this stage of development.
Approved indications
Common side effects
Key clinical trials
- Corneal Crosslinking Treatment Study (PHASE4)
- Transepithelial Corneal Cross-linking Using Iontophoresis (NA)
- Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders (PHASE3)
- Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia (PHASE3)
- Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL) (NA)
- Standard Versus Transepithelial Corneal Crosslinking (NA)
- T-Cat Laser & Cross-linking for Keratoconus (NA)
- Treatment of Keratoconus Using Collagen Cross-Linking (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ricrolin+ CI brief — competitive landscape report
- Ricrolin+ updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI